Found this article earlier - IGF1 seems to be showing preliminary efficacy in another type of autism.
http://sfari.org/news-and-opinion/c...or-shows-promise-for-phelan-mcdermid-syndrome
Augurs well for nnz-2566.
If we can manage FDA approval for Rett, it really does open the doors across the autism spectrum - truly a class effect!
Wider autism efficacy potential for nnz-2566
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.77 |
Change
-0.200(1.00%) |
Mkt cap ! $2.523B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.96 | $19.69 | $2.740M | 138.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 984 | $19.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.77 | 1047 | 13 |
View Market Depth
| Last trade - 15.02pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |